Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023, Wednesday, November 30, 2022 09:50 a.m.- (JST). Eisai Corporation of North America & Its Subsidiaries's Income Statement (based on Industry Averages) Sustainable Access and Pricing Transparency Report. Read more, Our Response to the Novel Coronavirus Infection, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Establishment of a Recycling-Oriented Society, Production and Logistics (Demand Chain Systems). Slide download: BKZ Long-Term Data in PSO. Briefing on Pharmaceutical Segment [June 19, 2017] Data Book. WOODCLIFF LAKE, N.J., Nov. 2, 2020 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and research from the company's Alzheimer's disease (AD) pipeline, including BAN2401, anti-microtubule binding region (MTBR) tau antibody E2814 and lemborexant. Engineer with experience in design, quality assurance, and regulatory affairs of medical devices with an emphasis on the safe and secure end-user experience. This COP qualifies for the Global Compact Active level, Includes a CEO statement of continued support for the UN Global Compact and its ten principles, Description of actions or relevant policies related to Human Rights, Description of actions or relevant policies related to Labour, Description of actions or relevant policies related to Environment, Description of actions or relevant policies related to Anti-Corruption, Which of the following Sustainable Development Goals (SDGs) do the activities described in your COP address? Mary Ann Clothing. January 20, 2020. EBARA Way. Since the January 2018 publication of our article on how Eisai Co., Ltd. creates corporate value from investments in nonfinancial capital, i.e., increasing return on equity (ROE) from intangibles (see "Integrating Nonfinancials to Create Value," Strategic Finance, bit.ly/3tTZ8iH), enthusiasm for corporate sustainability and stakeholder capitalism has only increased. The 2020 Integrated Report continues the new digital and fully interactive format created in 2018. USING LIQUID BIOPSY TO ACCELERATE NEXT-GENERATION DRUG DISCOVERY AND DEVELOPMENT, DAYVIGO (LEMBOREXANT) APPROVED FOR TREATMENT OF INSOMNIA IN JAPANNON-SEDATIVE OREXIN RECEPTOR ANTAGONIST DEMONSTRATES EFFECTIVENESS FOR BOTH SLEEP ONSET AND SLEEP MAINTENANCE, APPROVAL OF ANTIEPILEPTIC DRUG FYCOMPA IN JAPAN FOR MONOTHERAPY AND PEDIATRIC INDICATIONS FOR PARTIAL-ONSET SEIZURES, AS WELL AS A NEW FORMULATION, Eisai Rated A, the highest rating in the CDP Climate Change Report 2019, LAUNCH OF ANTICANCER AGENT HALAVEN IN CHINA, FYCOMPA FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA. However, in About Eisai "Corporate Governance Report Notice" November 30, 2022 Nearly 20 kinds of Eisai's ESG investments have a delayed impact that affects long-term corporate value with statistical significance over a period of 5 to 10 years. SDG 1: End poverty in all its forms everywhere, SDG 2: End hunger, achieve food security and improved nutrition and promote sustainable agriculture, SDG 3: Ensure healthy lives and promote well-being for all at all ages, SDG 4: Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all, SDG 5: Achieve gender equality and empower all women and girls, SDG 6: Ensure availability and sustainable management of water and sanitation for all, SDG 7: Ensure access to affordable, reliable, sustainable and modern energy for all, SDG 8: Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all, SDG 9: Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation, SDG 10: Reduce inequality within and among countries, SDG 11: Make cities and human settlements inclusive, safe, resilient and sustainable, SDG 12: Ensure sustainable consumption and production patterns, SDG 13: Take urgent action to combat climate change and its impacts, SDG 14: Conserve and sustainably use the oceans, seas and marine resources for sustainable development, SDG 15: Protect, restore and promote sustainable use of terrestrial ecosystems, sustainably manage forests, combat desertification, and halt and reverse land degradation and halt biodiversity loss, SDG 16: Promote peaceful and inclusive societies for sustainable development, provide access to justice for all and build effective, accountable and inclusive institutions at all levels, SDG 17: Strengthen the means of implementation and revitalize the global partnership for sustainable development, Opportunities and responsibilities that one or more SDGs represent to our business, Where the companys priorities lie with respect to one or more SDGs, Goals and indicators set by our company with respect to one or more SDGs, How one or more SDGs are integrated into the companys business model, The (expected) outcomes and impact of your companys activities related to the SDGs, If the companies' activities related totheSDGs are undertaken in collaboration with other stakeholders, Other established or emerging best practices. Ratio of basic salary and remuneration of women to men. Ronak Patel is an Associate Director of Scientific Engagement and Digital Communications on Eisai's US Medical Affairs team. Eisai (OTCPK:ESALF): Q1 GAAP EPS of 85.20.Revenue of 165.58B (+7.5% Y/Y)Press Release Diversity of governance bodies and employees. 2016. Ltd. ("the Company") discloses its consolidated financial statements in accordance with the International Financial Reporting Standards (IFRS). 2016 Integrated Report 3.6 MB. ESG Data and Independent Assurance. The Texas Integrated Report describes the status of the state's waters, as required by Sections 305(b) and 303(d) of the federal Clean Water Act. Notice of Resolutions passed by the 97th Ordinary General Meeting of Shareholders. Published. Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 Study, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPAN, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIES, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASE, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPAN, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using Blood, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's Disease, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORM, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIAL, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGY, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCE, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITIS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care products, FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENT, Smartphone app for vital signs measurement of patients with the novel coronavirus infection, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDED, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers Disease, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONG, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVID, EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICA, The effect of SEI-I* evokes the joy of eating, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDS, DAYVIGO (LEMBOREXANT) APPROVED FOR TREATMENT OF INSOMNIA IN JAPAN. This website uses cookies to enhance your browsing experience. January 10, 2020. 2023 Release; The Group's revenue increased significantly primarily due to the continuous growth of global brands such as anticancer agent Lenvima and an upfront payment of 49.6 billion from Bristol Myers Squibb (the U.S.) under strategic collaboration for antibody drug conjugate MORAb-202. Learn more about Eisai today. (2) The Company's mission is the enhancement of patient satisfaction. Introduction April 2019 - March 2020 Files. DISCLAIMER. Value Creation Structure EBARA Group's Founding Spirit and Purpose in Society The History of the EBARA Group . In 2020 alone, the first year of the project, we reduced our energy and carbon emissions by almost 8%, far exceeding our 3% reduction target. For FY 2020 286,616,063 For FY 2019 286,506,432 The Company's shares held . EBARA Group at a Glance. . EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 StudyFirst Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPANIf approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimers diseaseAducanumab is now under regulatory review in Japan, Europe and the United States, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIESThis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of-synuclein misfolding and aggregation, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING, AbbVie and Eisai Announce an approval for additional indication of HUMIRA, a fully Human Anti-TNF Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASEWITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS, EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPANA once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies, EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaLENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibResults of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using BloodThe Content Presented at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference, Update on FDA Advisory Committees meeting on aducanumab in Alzheimers disease, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's DiseaseIf approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease and to meaningfully change the course of Alzheimers disease, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMERS DISEASE CONFERENCE, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORMAiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIALAMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19AMGENS APREMILAST AND EISAIS ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK, Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies, NOTICE REGARDING BIOGENS DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMERS DISEASE, SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGYEstablishment of Social Cooperation Program Protein Degradation Drug Discovery, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCEAdopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)", Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITISFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials, EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy, EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020, EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020, EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productsEISAI TO LAUNCH SAHNE MEDICAL SPRAY AND SAHNE MEDICAL CREAMSahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid, EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020), FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewPriority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimers disease, EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN, APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENTEISAI DEMENTIA PLATFORM EASIIT COMMENCES, EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020, Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED projectPreventing medical infrastructure collapse by a monitoring system linked to LINE, INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMERS DISEASE, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDEDRESEARCH ACTIVITIES COMMENCE, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseIf approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimers disease, Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONGFIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN, EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN, NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA LAUNCHED IN JAPAN, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVIDGCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORANS INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTIONEISAIS ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, EISAI RECEIVES APPROVAL FOR PARKINSONS DISEASE TREATMENT EQUFINA IN SOUTH KOREA, SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS, CONTINUATION OF POLICY FOR PROTECTION OF THE COMPANYS CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN), EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICASUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM, BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL NOUKNOW TO BE USED IN BEAUTY SALONS, EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA, AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA, a Fully Human Anti-TNF Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa, Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting, The effect of SEI-I* evokes the joy of eatingEISAI TO LAUNCH NEW SELBELLE PREMIUM TABLETS AND NEW SELBELLE PREMIUM FINE GRANULESThe first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes, EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING, EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING) BY INSTITUTIONAL INVESTOR MAGAZINE, Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA, DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 20, EISAI TO LAUNCH DIGITAL TOOL NOUKNOW IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), All-case Surveillance Condition for Approval of Actonel 17.5 mg tablets for Treatment of Pagets Disease of Bone Cleared in Japan, Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDSFOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA, EISAI TO SUPPORT COUNTER MEASURES FOR CHINAS NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA, EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC.

Mobile Homes For Rent In Stanley, Nc, Sweetest Cigar Wrapper, 750 's Ironwood Dr Apache Junction Az 85120, Connecting 3 6 Gauge Wires, Claudia Wells Sebastian Wells, Articles E